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 Traditionally, threonyl-tRNA synthetase (ThrRS) has been studied for its canonical 
function of aminoacylation. Recently, however, the enzyme has been identified as a potent 
angiogenic factor. Both functions are influenced by a structural change within the enzyme. Upon 
binding of a specific inhibitor, borrelidin (BN), an alternative conformation is adopted, 
preventing angiogenic function. Mutant versions of ThrRS were generated using site-directed 
mutagenesis to mimic the BN-bound structure. The effects of these mutations on threonine-
induced conformational changes were explored using steady state fluorescence. The greatest 
conformational impairment was seen with A460S and S488W which demonstrated 38% and 41% 
of the control response, respectively. Additionally, differential scanning fluorimetry was utilized 
to detail complex stabilization upon substrate binding. Specifically, the binding of threonine 
increased the melting temperature of the wild type enzyme by 9.82 °C, but had reduced effects 
on the other mutations, with S488W displaying the least (1.84 °C). Borrelidin binding was found 
to induce a biphasic melting trend for the wild type, S488W, and A460S constructs, in agreement 
with the proposed two-step binding mechanism by Ruan, et al. Future studies include: (i) 
investigating angiogenic potential of each construct using in vivo tube formation assay, and (ii) 









 Aminoacyl-tRNA synthetases (aaRSs) are an important class of enzymes that catalyze the 
attachment of amino acids to their corresponding tRNA in a process known as aminoacylation. 
The product of this reaction, referred to as charged-tRNA, is subsequently targeted to the 
ribosome to donate amino acids to an emerging polypeptide, resulting in the formation of a 
functional protein [1]. For all aaRSs the generation of charged tRNA proceeds through a 
conserved, two-step mechanism:   
 E + AA + ATP ⇌ E ● AA—AMP + PPi             (1) – Adenylate  
 E ● AA—AMP + tRNAAA ⇌ E + AA—tRNAAA + AMP           (2) – Aminoacyl-tRNA 
In the first step of the reaction, known as activation, the amino acid (AA) is condensed with ATP 
to form an aminoacyl-adenylate intermediate. The formation of the adenylate species prepares 
the amino acid for its subsequent transfer to the terminal 2’ or 3’ hydroxyl group of the awaiting 
tRNA molecule. In addition to performing this important biological process, many aaRSs 
provide non-traditional secondary functions to the cell as well. 
 Recently, a growing body of evidence has revealed a diverse set of secondary functions 
among aaRSs: RNA splicing activity, transcriptional regulation, and stress signals including 
apoptosis and inflammation [1]. For instance, leucyl-tRNA synthetase possesses splice activity 
associated with excision of group I introns [2]. A second example is glutaminyl-tRNA 
synthetase, which operates to oppose a pro-apoptotic signaling pathway initiated by apoptosis 
signal-regulating kinase 1 [3]. Threonyl-tRNA synthetase (ThrRS) serves as a pro-angiogenic 
factor in response to specific signaling molecules in the cell [4].  
(7) 
 Angiogenesis is a process of new blood vessels formation from pre-existing ones.  The 
regulation of this effort is governed by the balance of positive and negative signals. Under 
normal conditions, blood vessels will release angiogenesis-inhibitory factors, such as 
angiopoetin-1 to maintain a quiescent state.  However, in response to hypoxia, inflammation, or 
wound healing cells will release pro-angiogenic growth factors and chemokines. The most 
important of these signals is vascular endothelial growth factor (VEGF) which binds to the 
VEGF receptor 2 (VEGFR2) and activates downstream signaling cascades involved in the 
proliferation and migration of endothelial cells. Interestingly, in a recent study we have 
demonstrated that exposure of cells to VEGF or tumor necrosis factor-α (TNF-α) will stimulate 
the release of ThrRS in the extracellular space [4]. Furthermore, in vitro assays showed that 
adding exogenous ThrRS to low serum media in endothelial cell tube assays resulted in a 
significant increase in blood vessel branching and generation. It has been proposed that ThrRS 
promotes angiogenesis via induction of endothelial cell migration. 
 Suppression of blood vessel development has important implications in the fight against 
cancer. Initially the growth of many tumors is restricted by apoptosis associated with the hypoxic 
and nutrient deprived state of the tissue. However, eventually a small population of cells within 
the tumor acquires the ability to stimulate the growth of new capillaries and alleviate the former 
growth restraint.  Referred to as the ―angiogenic switch‖ this sudden increase in tumor 
vascularity provides the nutrients and migration capacity required for metastatic progression. 
Because angiogenesis is one of the key processes assisting transformation of cancer from the 
benign to malignant state, inhibition of ThrRS has important pharmaceutical implications [5]. 
When ThrRS is inhibited by the naturally-occurring antibiotic, borrelidin (Figure 1) (BN), 
metastasis can be suppressed [6-8]. 
(8) 
 Inhibition of ThrRS by BN displays noncompetitive kinetics. Binding occurs in a 
biphasic manner, with the second step resulting in enzyme isomerization and ultimately taking a 









In this scheme EI is classified as the encounter complex, which forms under rapid equilibrium, 
and E
*
I represents the slow forming, higher affinity enzyme-inhibitor complex. The affinity of 
BN for ThrRS is extremely high: Ki
app
 = 3.7 + 0.3 nM [10]. 
 Although BN binding displays noncompetitive kinetics, its mechanism resembles 
competitive modality. The binding of BN to ThrRS occurs in quadrivalent fashion. Occlusion of 
all three substrate binding sites occurs. Furthermore, the C4-C14 moiety of BN infiltrates a 
hydrophobic pocket adjacent to the active site [11]. During uninhibited conditions the 
threonine—ThrRS interaction elicits a ―closing‖ of the enzymatic cleft, resulting in a 14° 
geometrical shift in an active site α-helix (residues D431-N448) (Figure 2) [11]. However, the 
presence of BN will induce a geometrical shift in the opposite direction. This results in a 
―locking‖ of ThrRS in its native conformation.  
 Examining the cleft closure associated with binding of canonical substrate is of current 
interest. It is unknown if this conformational change is crucial for effective aminoacylation 
activity of the enzyme. When BN is present, the conformational change is not permissible and 
thus aminoacylation cannot occur. However, it is not clear if this is due to the steric hindrance of 
the large, 18-carbon macrolide inhibitor. By locking the enzyme in the inhibited conformation, 
without the presence of BN, it can be examined as to how crucial the ―closing‖ of the enzymatic 
(9) 
cleft is. Understanding this mechanism of inhibition is significant due to the severe toxicity of 
BN [12]. Although BN will inhibit the pro-angiogenic function of ThrRS, it also prevents 
functional aminoacylation. In recent studies this has led to death of the organism by way of the 
amino acid starvation response [12]. Alternative drug therapies have been developed to inhibit 
ThrRS with regards to angiogenesis but still allow native aminoacylation activity to occur [12]. 
 Locking ThrRS in its native conformation can be completed by substitution of a smaller 
residue with a bulkier amino acid, such as tryptophan, in to the enzymatic cleft. This insertion 
will behave as a ―prop,‖ preventing the enzymatic cleft from closing when canonical substrate is 
inserted. Mutant ThrRS will exhibit a conformation similar to the BN-inhibited wild type 
enzyme (Figure 3). Target ThrRS mutations were developed by utilizing work completed for 
human threonyl-tRNA synthetase (TARS) constructs: Q566W, A538W, and R442A [13]. 
Equivalent mutations were designed in E. coli ThrRS for this study using PyMOL. 
 Mutant constructs should not undergo a conformational change associated with the 
binding of canonical substrate, namely threonine. To investigate whether a conformational 
change occurs in the presence of substrate, steady state fluorescence was utilized [14]. Steady 
state fluorescence was used to measure the conformational change of the enzyme. This method 
monitors the fluorescence activity of a tryptophan residue (W434) located adjacent to the 
enzyme’s core [14]. Fluorescence activity is a function of the chemical environment of this 
residue. When threonine binds to wild type ThrRS a structural change occurs, changing the 
chemical nature of the tryptophan residue, resulting in a fluorescence decrease, or quench. 
 In the presence of canonical substrate a conformational change of wild type ThrRS 
occurs to stabilize the complex. When the conformational change cannot occur enzyme stability 
(10) 
should not increase. To explore enzyme stability, differential scanning fluorimetry will be used 
[15]. With increased stability a higher melting point should be observed. For wild type this 
means a higher melting point should be observed when canonical substrate is bound. The mutant 
ThrRS constructs should not display this trend.  
 The rate of aminoacylation activity must be high enough such that the enzyme can 
cooperate with the activity of the ribosome and all other aaRSs during translation. Measuring the 
rate of this process can be completed by measuring the aminoacylation activity during steady 
state conditions [16]. It is predicted that the mutant enzymes will observe a diminished 
aminoacylation rate due to the inhibited conformational change. 
 The aforementioned substitutions were successful in diminishing the conformational 
change of the enzyme in response to threonine. As a result aminoacylation activity as well as 
Thr:ThrRS complex stability was decreased. This shows support for the necessity of the 
conformational change in normal functioning of the enzyme. Due to the presence of BN in the 
enzymatic cleft a conformational change of the enzyme is prevented and thus canonical activity 
is eliminated. Future studies on the effects of the ThrRS mutants on aminoacylation potential 







II. Methods and Materials 
 
Mutant ThrRS Design 
 Appropriate enzyme mutations were modeled using the PyMOL molecular graphics 
system [17]. All mutations were designed to disrupt the conformational change associated with 
aminoacylation of ThrRS. This was completed by substitution of a residue adjacent to the 
binding pocket with a bulkier amino acid. Human ThrRS mutants which have been previously 
found to produce similar conformational change disruption were utilized as a template for E. coli 
ThrRS mutant development [13]. Mutants developed included A460S, R363W, and S488W. 
Site-Directed Mutagenesis 
 Mutations of the ThrRS enzyme were completed using the QuikChange II Mutagenesis 
kit provided by Agilent Technologies [18]. Forward and reverse primers were developed to 
encode the parent plasmid with the appropriate mutations. After the primers bound to the parent 
plasmid DNA elongation was completed using PfuUltra HF DNA polymerase by the PCR 
method. An important reagent for successful mutagenesis was the Quik-Solution, provided by 
the QuikChange II XL Kit. This prevents the plasmid from supercoiling during replication. 
Isolation of the mutant plasmid was completed by digestion of the parent plasmid by the 
endonuclease Dpn I. This process occurs by breakdown of plasmid strains which contain 
methylated nucleobases. To check for the presence of mutant plasmid following digestion, 
agarose gel (0.8%) electrophoresis was completed. 
 Mutant plasmid was transformed into E. coli competent cells (JM-109) (Promega). 
Uptake of mutant plasmid into the organism was accomplished by heat-shock at 42 °C for 50 
(12) 
seconds. Organism recuperation was required following heat-shock and was completed by using 
a 1 hour regrowth period in SOC medium at 37 °C. SOC medium contains glucose, ions, and 
polypeptides. Bacterial colonies were then generated on LB plates containing 10 mg/L 
tetracycline overnight (16-18 hours). Colonies were harvested and cultured in 5 mL LB/tet broth. 
Mini-prep was completed for each colony to harvest plasmid DNA. This process separates whole 
plasmid from the remainder of the organism, including fragmented nucleobases. Sequencing of 
the entire mutant gene was completed at the DNA Facility at the University of Vermont and was 
analyzed using Sequencher. 
ThrRS Purification 
 Enzyme expression was regulated by the lac operon [19]. Mutant bacterial strains were 
cultured in 1.5 L of LB-broth at a tetracycline concentration of 10 mg/L to a cell density of A280 
= 0.6. Induction of the ThrRS gene was completed for 5 hours using isopropyl 1-thio-β-D-
galactoside (IPTG) at a concentration of 1 mM. A bacterial pellet was resuspended in sonication 
buffer (20 mM potassium phosphate buffer pH 8.0, 100 mM KCl, 35 mM imidazole, 5 mM β-
ME). Cellular lysis followed by treatment of cellular debris with protamine sulfate (0.4%) was 
done to remove insoluble cellular components as well as nucleic acids. High pressure liquid 
chromatography (HPLC) purified ThrRS product from other proteins. Purified ThrRS products 
contain a His6-tag on their N-terminal end to permit chelation to a Ni-affinity column. Protein 
elution was completed using an imidazole gradient from 35 to 250 mM. Fractions were analyzed 
for the protein of interest using 8% SDS PAGE gels. ThrRS-containing fractions were pooled 
and dialyzed to remove imidazole. Enzyme concentration was completed using a 35000-MWCO 
membrane filter. Isolated protein was mixed with equivolume 80% glycerol for -20 °C storage. 
(13) 
A quantification of the enzymatically available active sites was measured by an active site 
titration, as described previously [16]. 
Steady-State Fluorescence 
 Intrinsic tryptophan fluorescence was measured using PTI technologies fluorimeter [14]. 
An excitation wavelength of 290 nm and an emission wavelength of 320 nm were used. ThrRS 
was suspended in a fluorescence buffer (20 mM Tris pH 7.5, 150 mM KCl, 15 mM MgCl2, 5 
mM β-ME) which was bubbled with argon gas prior to measurements. Measurements were made 
at an enzyme concentration of 100 nM; baseline enzyme fluorescence was equal to ~12-13x 
background. A titration of threonine over a range of 0.2-5.0 times the KD (KD=215 μM) was 
completed [14]. Consistent mixing was achieved using uniform pipetting after each addition of 
threonine. Measurements were made for 60 seconds at 1 count/sec. The average fluorescence 
value was calculated for each 60 sec measurement. Background and volume corrections 
(Vfinal/Vinitial) were completed for each measurement and then corrected for unity. A plot of 
protein fluorescence (a.u.) versus threonine concentration (μM) was generated using data 
collected in triplicate and fitted with a best-fit line using the Prism graphing software. 
Differential Scanning Fluorimetry 
 Enzyme stability was determined by measuring the melting temperature (Tm) of native 
and substrate-bound forms of ThrRS [15]. A fluorescently active dye, Sypro Orange, will 
produce signal upon binding to hydrophobic regions of the enzyme. At room temperature the 
hydrophobic regions of the enzyme are not accessible and thus a fluorescence signal will not be 
observed. A gradual increase in temperature (1 °C/min) was applied to the enzyme. At a well-
defined temperature protein unfolding occurred and the dye bound to the enzyme. An increase in 
fluorescence intensity was observed at the temperature at which the enzyme denatured (Tm).  
(14) 
 Melting point measurements were recorded for each enzyme in the presence of various 
substrates, including: threonine (5 mM), ATP (5 mM), BN (10 mM), and DMSO (which serves 
as the vehicle for BN). Binding of standard substrates, like Thr and ATP, were predicted to 
induce a conformational change of the enzyme, resulting in an increase of enzyme stability and 
thus an increase in Tm. The mutant enzymes wer predicted to not be able to undergo the same 
conformational change, and thus enzyme stabilization should not occur. The effect of borrelidin 
binding on the stability of the enzyme was measured using this method as well. It was predicted 
that borrelidin will increase the stability of the enzyme due to its tendency to lock the enzyme in 




 E. coli BL2(DE3) (New England Biolabs) cells expressing the tRNA
Thr
-containing 
plasmid, coding for E.coli tRNA
Thr
, were cultured in LB broth supplemented with 100 mg/ml 
ampicillin to a cell density of A280 = 0.6. Expression of tRNA
Thr
 was induced with 1 mM IPTG 
overnight.  Centrifugation was completed to harvest bacterial cells. The pellets were resuspended 
in suspension buffer (20 mM Tris pH 7.5, 20 mM MgCl2, 10 mM β-ME) and then agitated with 
equivolume phenol (pH = 4.8) to extract all RNA from the cells. The aqueous fraction was 
ethanol precipitated overnight, and extracted RNA was resuspended in 10 mM HEPES and 50% 
formamide. This solution was resolved using 8M Urea/10% polyacrylamide gel electrophoresis. 
The tRNA was identified by UV shadowing, electroeluted into 1x TBE buffer (0.45 M Tris base, 
0.45 M boric acid, 8mM EDTA pH 8.0), and then ethanol precipitated. The tRNA pellet was 
resuspended in 10 mM HEPES and stored at -20°C. The active concentration of tRNA
Thr
 was 
determined by the plateau charging assay [16].  
(15) 
Steady State Aminoacylation Assay 
 The aminoacylation activities of ThrRS constructs were determined using modifications 
to established steady state aminoacylation procedures [16]. Briefly, reaction mixtures consisted 
of 20 mM HEPES pH 8.0, 100 mM KCl, 10 mM MgCl2, 5 mM β-mercaptoethanol, 2 mM ATP, 
1 U pyrophosphatase (Roche), 80 µM threonine, 20 µM [
14
C]-threonine, and 30 µM tRNA
Thr
. 
Reactions were initiated with the addition of 10 nM ThrRS (quantified active sites) and run at 
37°C.  Aliquots were taken at varying time points and spotted onto Whatmann 3MM paper filters 
pre-soaked in 5% trichloroacetic acid (TCA). Upon completion, the filters were washed 3 times 





 was detected by scintillation counter and the activity determined by linear regression of 
threonyl-tRNA
Thr













Purifying ThrRS Constructs 
 Gene mutations were introduced via nucleobase substitution using the site-directed 
mutagenesis QuikChange II XL kit. The presence of plasmid following digestion (by Dpn I) was 
verified by agarose (0.8%) gel electrophoresis, suggesting the introduction of a successful 
mutation (data not shown). Mutant genes were analyzed at the University of Vermont DNA 
facility using Sequencher. The only mutations present in the genes were the desired substitutions.  
 The mutant plasmids were transformed into E. coli. The ThrRS gene was regulated by the 
lac operon which was induced using IPTG. A Ni-affinity column was used to purify ThrRS. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) verified that the 
molecular weight of the product was 74 kDa, indicating the correct molecular weight and that 
premature cleavage had not occurred during translation (Figure 4). 
Aminoacylation Activity 
 An active site titration was used to determine the percentage of enzymatically available 
active sites. This was measured by calculating the ratio of AMP produced at various kinetic time-
points, to the total amount of ATP initially added. It was determined that the wild-type and 
A460S constructs were 86% and 91% active, respectively. The S488W mutant was observed to 
be 51% active. Because the R363W mutant was kinetically inert (0% active), due to R363 being 
a crucial residue for threonine stabilization during catalysis, the total concentration as determined 
by absorbance was used for activity determination. 
(17) 
 The steady state aminoacylation assay was used to determine the activity of the enzymes. 
Measuring the rate of charged-tRNA production was determined by calculating the amount of 
charged tRNA produced per active site at various time points (0-3 min). This method was 
completed under conditions of excess canonical substrate. A linear trend in product formation 
was observed (Figure 5). Relative enzymatic rates were represented by the slope of the best-fit 
line. Each ThrRS construct was demonstrated to be enzymatically active, except for the R363W 
mutant, as expected. Wild type ThrRS exhibited active sites which produce charged-tRNA at the 
highest rate, while S488W and A460S showed slower production (Table 1). 
Threonine-Induced Conformational Change 
 Monitoring the conformational change of ThrRS associated with threonine binding was 
completed using stopped flow fluorescence, namely intrinsic tryptophan fluorescence. A range of 
threonine concentrations equal to 0.2–5 times KD (215 μM) was added to 100 μM enzyme. This 
resulted in a decrease, or quench, of total fluorescence intensity. Each measurement was 
background and volume corrected. Because this method is not absolute and collects relative data 
points it was important to correct measurements for unity in order to compile data sets.  
 Every addition of substrate resulted in a quench in fluorescence intensity. However, the 
magnitude of the fluorescence decrease was not uniform with equimolar additions of threonine. 
Shown in Figure 6 is the titration curve for each enzyme. A saturation of the conformational 
change was observed with each ThrRS construct. The conformational change of each mutant was 
not as intense as was observed for wild type. This trend is emphasized in Table 2 which 
quantifies the magnitude of the conformational change for each enzyme relative to wild type. 
The A460S mutant responded minimally to the presence of threonine (37.6%), while R363W 
observed the greatest conformational change (63.0%). 
(18) 
Enzyme Stability as a Function of Substrate-Binding 
 Monitoring enzyme stability was completed by measuring the melting temperature (Tm) 
of the enzymes in the presence of various substrates. These substrates included threonine and 
ATP (Figure 7a-d). An increase in Tm due to the presence of substrate indicated enzyme 
stabilization. This was observed with the binding of threonine. A maximum stabilization of the 
enzyme was observed with wild type, with a ∆Tm of 9.82 °C (Table 3). The S488W mutant was 
relatively unresponsive to threonine, which observed a ∆Tm of 1.84 °C. By this method, ATP and 
DMSO binding was found to not affect the melting temperature of the enzyme (Table 4).  
 BN binding was found to induce a biphasic melting pattern for all of the enzymes, except 
R363W ThrRS (Figure 8). This may be attributed to a two-step unfolding process, with each 
unfolding element occurring at a separate temperature. A best-fit line could not be adjusted to 
these data due to the limited mobility of this method, and thus Tm could not be calculated. 
Additionally, the A460S and WT enzymes observed nearly identical melting curves in the 
presence of BN. The fluorescence fluctuation, indicated with SEM error bars, is minimal for the 












 The production and purification of the S488W, A460S, and R363W ThrRS mutants was 
completed successfully. Verification of the molecular weights of these compounds by SDS-
PAGE showed that premature cleavage of the enzyme had not occurred; a stop codon was not 
erroneously inserted during mutagenesis. Furthermore, a fluorescence quench was observed in 
the presence of threonine.  A conformational change in response to canonical substrate indicates 
proper enzyme folding. 
 Activity site titration showed that the wild type and A460S active sites were active at ≥ 
90%, and the S488W mutant was found to be 50% active. ThrRS exists as a dimer. The S488W 
mutation may have caused a disruption of the dimeric interface, resulting in 50% enzyme 
activity. Differential scanning fluorimetry also indicated a potential for misfolding with a more 
intense fluorescence signal at baseline. A greater density of hydrophobic residues was exposed in 
the native conformation. This may be due to the enzyme being partially unfolded. The possibility 
of disrupted dimeric interactions and/or improper folding of S488W will be investigated further 
by measuring the enzyme structure using circular dichroism (CD) and X-ray crystallography. 
Inhibition Mechanism of Borrelidin Binding 
 The binding mechanism of BN has been proposed as slow, tight binding by Ruan et al. 
[10]. This is characterized by a two-step mechanism, described by an encounter, low-affinity 
complex followed by enzyme isomerization to form a much higher affinity complex [11]. 
(20) 
Biphasic protein unfolding trends of the wild type-, S488W-, and A460S- ThrRS:BN complexes 
were consistent with this mechanism. Each unfolding event may correspond to an analogous 
binding phase.  
 An alternative trend was observed with the R363W:BN complex, however. This complex 
experienced monophasic melting. This may have been caused by the bulky nature and location of 
the substitution. This is located in the active site of the enzyme; concomitant with the binding 
site of BN. Due to the insertion of this bulky residue in to the binding pocket of BN full spectrum 
inhibition was not permissible. Because partial enzyme stabilization was observed in the 
presence of threonine, it is suggested that the encounter complex does form, however. 
Substrate-Induced Stabilization was Reduced with Mutants 
 During the intrinsic tryptophan experiments, saturation of the conformational change was 
reached for each construct. However, the fluorescence quench was less intense for the mutants. 
These trends indicate a lesser conformational change induced upon threonine binding. The 
bulkier substitutions utilized for the A460S and S488W mutants behaved as a ―prop,‖ preventing 
full closure of the enzymatic cleft. This trend is identical to that observed with the wild type 
ThrRS:BN complex [10]. 
 A diminished conformational change in response to threonine was also observed using 
differential scanning fluorimetry. Enzyme stabilization in the presence of threonine was greatest 
for wild type (9.82 °C). On the contrary, the S488W mutant observed< 2 °C stabilization. These 
results are in agreement with the intrinsic tryptophan fluorescence data. S488W did not undergo 
a large conformational change and thus was not able to stabilize its structure to the same degree 
(21) 
that wild type did. Again, the bulky substitution prevented enzymatic cleft closure, resulting in 
less of a conformational response to substrate. 
 Although the R363W mutant responded with the largest mutant conformational change, 
the complex was only stabilized by 3.38 °C, or 34% of wild type. The reason this mutant 
observed a large conformational change, which did not result in an equivalent stabilization of the 
complex, is because this mutation disrupts a key binding residue of threonine to the enzyme [20]. 
Destabilization of the binding complex had occurred. Partial binding of the amino acid resulted 
in a conformational change of the enzyme, but the incomplete bonding as well as the insertion a 
bulky residue into the binding pocket, prevented complete complex stabilization.   
 The conformational and stability trends of A460S are currently unexplainable with the 
current model. A conformational analysis indicated that the smallest degree of conformational 
change is occurring, whereas differential scanning fluorimetry showed that significant enzyme 
stabilization occurs in the presence of threonine (6.97 °C). This may have been due to the 
incorporation of a hydrophobic residue into the enzymatic cleft of the enzyme. The serine 
residue may be interacting with threonine to stabilize the complex. To investigate this further a 
titration of the enzyme with borrelidin will be completed using intrinsic tryptophan fluorescence.  
Conclusions 
 The importance of the conformational change associated with canonical activity of 
ThrRS was investigated successfully in this study.  A S488W and A460S substitution resulted in 
an enzymatic ―prop,‖ preventing the full conformational action of ThrRS. As a result enzyme 
stabilization in the presence of threonine, as well as aminoacylation activity was diminished. 
Additionally, the S488W mutation may have also resulted in the loss of positive cooperativity. It 
(22) 
was also shown that the R363W substitution prevented stabilization of the molecule, as well as 
induced a complete inhibition of canonical activity due to this being a key binding residue of 
threonine. Finally, although the conformational change induced by the A460S mutation was 
minimal, a large stabilization of the Thr:ThrRS complex had occurred. These are contradictory 
phenomenon. This will be investigated further using alternative titration approaches.  
 Future studies include investigating in vitro effects of these mutations on angiogenesis 
using the tube formation assay, as described by Williams, et al. [4] This assay will determine the 
vitality of the conformational change with regards to angiogenesis. It is predicted that because 
S488W resembles the BN-bound wild type complex it will display minimal angiogenic activity. 
Wild type and R363W constructs are expected to induce angiogenesis due to their 














V. Tables and Figures 
 
Figure 1. Planar depiction of the 18-membered macrolide inhibitor, borrelidin. 
Figure 2. An extrusion of an active site helix is prevented when ThrRS is bound to BN (yellow). 
A conformational change of varying magnitude occurs during the binding of various substrates 
to ThrRS: threonine (cyan; PDB-1EVK), tRNA
Thr
 (green; PDB-1QF6), a threonyl adenylate 
analogue (purple; PDB-1NYQ). An overall difference in the conformational change of this helix 
is observed to be 14°. 
Figure 3. Native conformations of wild-type (left), inhibited (center), and S488W (right) ThrRS 
constructs. In the presence of threonine cleft closure occurs for WT; BN binding prevents this 
conformational change. S488W is designed to mimic the inhibited conformation. 
Figure 4. An 8% SDS-PAGE gel indicated that isolated protein was the correct molecular 
weight (74 kDa) for each construct. Lane 1: wild type (2 mg/mL); Lane 2: S488W (2 mg/mL); 
Lane 3: A460S (2 mg/mL); Lane 4: R363W (2 mg/mL). 
Figure 5. Aminoacylation activity of the ThrRS constructs in the presence of excess substrate. 
This assay was used to quantify the amount of charged-tRNA produced per quantified active site 
per unit time. Wild type ThrRS was the most active, S488W and A460S were comparable, and 
R363W was considered kinetically inert. 
Figure 6. Intrinsic tryptophan fluorescence of the WT, S488W, A460S, and R363W ThrRS 
constructs in response to an increasing concentration of threonine. A fluorescence decrease, or 
quench, is characteristic of a conformational change upon substrate binding. The R363W mutant 
(24) 
displayed the most fervent conformational change relative to control, and A460S and S488W 
were comparable. 
Figure 7a-d. Enzyme stability as a function of substrate present. The inflection point of the 
curve represents Tm of the complex. Data points were calculated using a 9-point SEM average 
for every degree Celsius from 26-95 °C. Reaction conditions are color coded as: blue: without 
substrate; red: Thr; green: ATP; purple: DMSO. 
Figure 8. Melting curves for the ThrRS:BN complexes were indicative of a biphasic melting 
trend for WT (blue), S488W (red), and A460S (green). The R363W (purple) mutant was 
considered to be monophasic. 
Table 1. Aminoacylation activity of the ThrRS constructs as quantified by the slope of the steady 
state fluorescence curves. A larger slope represents a faster production of charged tRNA. The 
relative percent of activity of each mutant is shown in relation to the rate of wild type. 
Table 2. The magnitude of the conformational changes recorded for each enzyme in response to 
a titration of threonine. Mutant conformational changes are presented in reference to the 
conformational change of WT ThrRS (%). 
Table 3. Effects of threonine binding on the stability of ThrRS was system dependent. 










































































A m in o a c y la tio n  A c tiv ity  o f T h rR S

































1 0 0 0
W T
S 4 8 8W
A 4 6 0 S























T h r e o n in e   T it r a t io n






















S 4 8 8W
A 460S

























































T h rR S :B N  M e lt in g  C u rv e s
































WT ThrRS S488W ThrRS A460S ThrRS R363W ThrRS 
Slope 221.6 ± 17.65 
182.1 ± 12.89 
(82%) 
165.5 ± 6.049 
(75%) 


















Enzyme ∆(a.u.) % of WT 
WT 0.27 100.00 
S488W 0.11 40.79 
A460S 0.10 37.57 

















E. coli Untreated Thr ∆Tm 
WT 53.26 63.08 9.82 
S488W 50.56 52.4 1.84 
A460S 53.09 60.06 6.97 

















E. coli Untreated ATP ∆Tm 
WT 53.26 53 - 0.26 
S488W 50.56 50.75 0.19 
A460S 53.09 53.5 0.41 
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